Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 15/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538804 | 0.90 | MYB (0.84) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8544035 | 0.87 | MYB (0.73) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8539335 | 0.86 | MYB (0.75) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL9178595 | 0.85 | MYB (0.61) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL31237908 | 0.84 | MYB (0.83) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8809691 | 0.84 | MYB (0.60) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8539602 | 0.83 | MYB (0.71) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8538269 | 0.83 | MYB (0.76) | MYBCYP1A2GAAMAPTMEN1 | |
| SCHEMBL8112822 | 0.83 | MYB (0.58) | MYBCYP1A2MAPTLMNAKDM4E | |
| SCHEMBL8112856 | 0.83 | KDM4E (0.73) | MYBCYP1A2GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537949-B1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY CO ELI (GB) | 1998-07-01 | — | — | EP | disclosed |
| EP-0618206-B1 | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5576325-A | TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5574034-A | TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5571818-A | FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR | ELI LILLY AND COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514699-A | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| EP-0618206-A1 | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-5284868-A | Naphthopyran derivatives; for autoimmune diseases, cancer | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5281619-A | Administering naphtho(1,2-B)pyran derivatives | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0537949-A1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY INDUSTRIES LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |